 ROCKVILLE, Md., April 27, 2021 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today announced that the Company expects to report business results for the first quarter of 2021 after the market closes on Wednesday, May 5, 2021. 